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Alzheimer’s disease (AD) is a complex genetic disorder with no effective treatments. More than 20
common markers have been identiﬁed, which are associated with AD. Recently, several rare variants
have been identiﬁed in Amyloid Precursor Protein (APP), Triggering Receptor Expressed On Myeloid Cells
2 (TREM2) and Unc-5 Netrin Receptor C (UNC5C) that affect risk for AD. Despite the many successes, the
genetic architecture of AD remains unsolved. We used Genome-wide Complex Trait Analysis to (1) es-
timate phenotypic variance explained by genetics; (2) calculate genetic variance explained by known AD
single nucleotide polymorphisms (SNPs); and (3) identify the genomic locations of variation that explain
the remaining unexplained genetic variance. In total, 53.24% of phenotypic variance is explained by
genetics, but known AD SNPs only explain 30.62% of the genetic variance. Of the unexplained genetic
variance, approximately 41% is explained by unknown SNPs in regions adjacent to known AD SNPs, and
the remaining unexplained genetic variance outside these regions.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia,
affects an estimated 5.3 million people in the United States and is
the only 1 of the top 10 causes-of-death with no disease-altering
treatments (Ridge et al., 2013a). Most of the affected individuals
succumb to disease within 7 years of diagnosis. As the disease
progresses, affected individuals eventually require fulltime care,
which exacts a substantial emotional and economic burden on
families of affected individuals and society at large. Currently, AD, Brigham Young University,
090.
nd of the article.
Inc. This is an open access article ucosts the health care system in the United States more than $200
billion annually (Alzheimer’s Association, 2015). As the population
ages, AD incidence is expected to rapidly increase (projected to be
13.8 million affected individuals in 2050), which will cause
tremendous suffering for affected individuals and their families,
and health care systemsworldwide (costs are expected to exceed $1
trillion annually by 2050 [Alzheimer’s Association, 2015]).
AD can be classiﬁed as either early- or late-onset, with most of
(>99%) cases being late-onset. Early-onset AD is characterized by
autosomal dominant mutations in 1 of 3 genes (presenilin 1, pre-
senilin 2, or amyloid precursor protein). The genetic architecture of
late-onset AD is more complex. To date, more than 20 distinct
genetic loci have been implicated in AD by genome-wide associa-
tion studies (GWAS) and linkage studies (Lambert et al., 2013), and
additional rare variants in several genes have been identiﬁednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Genes and/or SNPs that affect risk for Alzheimer’s disease
Gene Disease SNP Effect of minor
allele
GWAS SNPs with strongest evidence
BIN1 (Bifﬁ et al., 2010; Naj et al., 2011) rs744373 Risk
CLU (Lambert et al., 2009) rs11136000 Protective
ABCA7 (Hollingworth et al., 2011) rs3764650 Risk
CR1 (Lambert et al., 2009) rs3818361 Risk
PICALM (Corneveaux et al., 2010;
Naj et al., 2011)
rs3851179 Protective
MS4A6A (Hollingworth et al., 2011;
Naj et al., 2011)
rs610932 Protective
CD33 (Hollingworth et al., 2011;
Naj et al., 2011)
rs3865444 Protective
MS4A4E (Hollingworth et al., 2011;
Naj et al., 2011)
rs670139 Risk
CD2AP (Hollingworth et al., 2011;
Naj et al., 2011)
rs9349407 Risk
HLA-DRB5/HLA-DRB1
(Lambert et al., 2013)
rs9271192 Risk
PTK2B (Lambert et al., 2013) rs28834970 Risk
SORL1 (Lambert et al., 2013) rs11218343 Protective
SLC24A4/RIN3 (Lambert et al., 2013) rs10498633 Protective
DSG2 (Lambert et al., 2013) rs8093731 Protective
INPP5D (Lambert et al., 2013) rs35349669 Risk
MEF2C (Lambert et al., 2013) rs190982 Protective
NME8 (Lambert et al., 2013) rs2718058 Protective
ZCWPW1 (Lambert et al., 2013) rs1476679 Protective
CELF1 (Lambert et al., 2013) rs10838725 Risk
FERMT2 (Lambert et al., 2013) rs17125944 Risk
CASS4 (Lambert et al., 2013) rs7274581 Protective
Linkage studies (common SNPs only)
APOE (ε2 and ε4)
(Corder et al., 1994;
Pericak-Vance et al., 1991;
Saunders et al., 1993)
rs7412/rs429358 Protective/Risk
Rare and other SNPs
APP (Goate et al., 1991;
Jonsson et al., 2012)
Multiple Both
PSEN1 (Sherrington et al., 1995) Multiple Risk
PSEN2 (Levy-Lahad et al., 1995) Multiple Risk
EPHA1 (Hollingworth et al., 2011;
Naj et al., 2011)
rs11771145 Protective
TREM2 (Guerreiro et al., 2012) rs75932628 Risk
UNC5C (Wetzel-Smith et al., 2014) rs137875858 Risk
GWAS SNPs in the top section of the table are described as “known GWAS SNPs” in
the text. All SNPs in the table were included in analyses of phenotypic variance in
regions of known AD SNPs.
Key: AD, Alzheimer’s disease; GWAS, genome-wide association studies.
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Despite these successes, the combined effects of these variants only
explain a fraction of the total estimated genetic variance of AD
(Ridge et al., 2013b).
Solving the genetic architecture of AD (i.e., identifying the
genomic variation that explains the remaining genetic variance of
AD) may provide the necessary insights into disease processes to
lead to the development of effective therapeutics. We recently
analyzed AD datasets to determine how much genetic variance
remained to be identiﬁed (Ridge et al., 2013b). In this article, we
report the results from an expanded analysis that improves our
previous study in two ways. First, we used a more densely imputed
dataset, and second, we incorporated common variants recently
identiﬁed by GWAS and rare variants into the study design. We
determined that approximately half of the estimated genetic vari-
ance of AD is unexplained by variants known to effect risk for AD,
and that remaining important variation is located throughout the
genome.
2. Methods
2.1. Dataset
In this work, we used a SNP dataset from the Alzheimer’s Dis-
ease Genetics Consortium. This dataset is the combination of 30
separate studies imputed by Naj et al. (Naj et al., 2011) using the
1000 Genomes Project as reference panel (Genomes Project et al.,
2012). We combined and prepared the data by the following: (1)
converted IMPUTE2/SNPTEST (Howie et al., 2011, 2009) format ﬁles
to PLINK (Purcell et al., 2007) allele calls and/or best guess genotype
(binary) format (uncertainty cutoff 0.1); (2) ﬁltered SNPs imputed
with low information (info < 0.5) from each dataset; (3) used the
default PLINK 1.9 (Purcell et al., 2007) uncertainty cutoff of 0.1
(i.e., any imputed call with uncertainty greater than 0.1 was treated
as missing); (4) removed duplicate SNPs from each dataset; (5)
ensured each SNP had the same strand orientation and genomic
coordinates in each dataset; (6) merged the datasets; (7) ﬁltered the
datasets using a minor allele frequency of 0.01 to retain common
SNPs; and (8) used directly genotyped (not imputed) SNPs for
identifying cryptic relatedness and for calculating principal com-
ponents (PCs) to account for population structure. There were
17,146 directly genotyped SNPs in common across all 30 studies,
none of which were symmetrical. We used PLINK to LD-prune these
SNPs using the following settings: maf 0.01, geno 0.02, indep-
pairwise 1500 150 0.2. These steps resulted in an LD-pruned,
directly observed, and nonambiguous dataset with 14,675 SNPs.
Finally, we used KING-Robust to identify the 28,730 participants
who were no more related than 3rd degree relatives (kinship
coefﬁcient 0.0442) and EIGENSTRAT (Price et al., 2006) to calculate
the ﬁrst 10 PCs for the 28,730 unrelated participants using the QC’d,
LD-pruned directly observed set of SNPs common to all 30 studies.
In summary, individuals more closely related than third cousins
were removed, 10 PCs were calculated using EIGENSTRAT (Price
et al., 2006), and SNPs with a minor allele frequency less than
0.01 were removed.
The initial dataset contained 28,730 samples. To perform these
analyses, we applied additional strict ﬁlters, speciﬁc to this
research, to this dataset. First, we removed any individuals missing
case/control status. Next, we removed any individuals missing one
or more covariates (age, sex, PCs). Finally, we removed any in-
dividuals missing data for any of the 21 known Alzheimer’s dis-
ease GWAS SNPs (Table 1, Supplementary Tables 1 and 2) or
Apolipoprotein E (APOE). APOE ε2 and ε4 alleles were treated as a
special case. The ε2 and ε4 alleles were directly genotyped for
most of the individuals in the dataset, whereas others hadimputed genotypes, and many had both. For these 2 alleles, if an
individual was directly genotyped for these alleles, or if there was
disagreement between the APOE genotypes by imputation and
direct genotyping, we used the genotypes from direct genotyping.
However, if only imputed genotypes were available for an indi-
vidual thenwe used imputed genotypes. In summary, we removed
any individual who was missing case/control status, age, sex,
principal components, APOE genotype for the ε2 or ε4 allele, or
genotype for any of the 21 known AD genes listed in Table 1, which
resulted in 19,031 samples being removed. The ﬁnal ﬁltered
dataset consisted of 9,699 individuals and 8,712,879 SNPs
(Table 2).
We created several additional datasets using PLINK (Purcell et al.,
2007), and covariate ﬁles using custom scripts, based on different
partitions from the original ﬁltered dataset described previously.
First, we created a dataset containing only the two APOE SNPs. Sec-
ond, we created a dataset with only SNPs from genomic regions of
known AD SNPs (Table 1). For the purposes of this research, we
deﬁned a genomic region as the 50-kilobases upstream and down-
stream of each gene named in the primary publication reporting the
association of different GWAS SNPs. For 2 different SNPs, rs9271192
Table 2
Demographics of the dataset used in this research
Category Mean age Cases Controls Totals
Male 77.79 1605 2358 3963
Female 77.57 2272 3464 5736
Total 77.70 3877 5822 9699
Table 3
Summary of results
SNP set Proportion of phenotypic
variance explained
(standard error)
Proportion of
genetic variance
explained
Variance explained
by all SNPs in the dataset
53.24% (0.0448) 100%
Variance explained by known AD SNPs:
Total variance
explained by
known AD SNPsa
16.30% (0.0448) 30.62%
APOE (ε2 and ε4 alleles) 13.42% (0.0447) 25.21%
All known GWAS SNPs,
except APOE SNPs
2.88% (0.0448) 5.41%
Variance explained by undiscovered AD SNPs:
Total variance
explained by
unknown AD SNPs
36.94% (0.0448) 69.38%
SNPs in regions of
known Alzheimer’s
disease SNPsb
15.24% (0.0348) 28.63%
SNPs outside regions
of known Alzheimer’s
disease SNPs
21.69% (0.0373) 40.74%
Key: AD, Alzheimer’s disease; GWAS, genome-wide association studies.
a Known GWAS SNPs refers to SNPs in top part of Table 1.
b Includes regions for all SNPs listed in Table 1. Regions are deﬁned as 50 kilo-
bases from the gene named in Table 1. Regions estimates were calculated using all
SNPs in the region except the known AD SNP.
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DRB5 and HLA-DRB1, and SLC24A4 and RIN3, respectively. For each
of these SNPs, we included both named genes. In addition to GWAS
SNPs, we included genes that contain rare variants that affect risk for
AD, and APP, PSEN1, and PSEN2, which contain functional variants
that cause early-onset AD and possibly harbor additional variants
that affect risk for late-onset AD (Table 1). Finally, we counted the
number of minor alleles of known GWAS SNPs for each individual
and included the genotype counts in covariate ﬁles to be used when
we wanted to control for known GWAS SNPs. So an individual could
have a count of 0 (indicating the individual is homozygous for the
major allele), 1 (indicating the individual is heterozygous for the
minor allele), or 2 (indicating the individual is homozygous for the
minor allele).
2.2. Genetic analyses
We used Genome-wide Complex Trait Analysis (Yang et al.,
2011) to estimate phenotypic and genetic variances for the
different partitions of SNPs as described previously. For each anal-
ysis, we controlled for age, gender, and PCs. For some of the ana-
lyses, we also controlled for dosage of known AD GWAS SNPs (as
described in the Results). For all analyses, we used a population
disease prevalence of 0.13 (Alzheimer’s Association, 2012).
3. Results
We estimated the proportion of the total phenotypic variance
explained by all SNPs in the combined dataset to be 53.24%. To
determine the phenotypic variance explained by known GWAS
SNPs with the strongest evidence for association with AD and the
two APOE alleles, we controlled for each of these SNPs, and created
an additional dataset with only the APOE alleles. Based on these
analyses, we estimated the phenotypic variance explained by
known GWAS SNPs to be 16%, of which 13% was explained by APOE,
and almost 3% explained by other genes.
A total of 37% of phenotypic variance is tagged by SNPs in our
dataset, but unexplained by known AD SNPs. To determinewhether
the unexplained phenotypic variance tagged by genetics is located
adjacent to known AD SNPs or throughout the genome, we created
an additional dataset with all SNPs located in regions of known AD
SNPs (Table 1). We deﬁned a region as 50-kilobases upstream and
downstream of the named GWAS gene, or the gene harboring a rare
variant. We found that 15% and 22% of phenotypic variance tagged
by known disease SNPs is located in regions adjacent to SNPs that
affect risk for AD and outside these regions, respectively. In sum-
mary, of the remaining phenotypic variance that can be explained
by unknown SNPs, approximately 41% is located adjacent to known
AD SNPs and 59% in other genomic regions. Results are summarized
in Table 3.
4. Discussion
Using data from 9,699 individuals and 8,712,879 SNPs, we have
carefully assessed the genetic variance for AD and the proportion
of that variance that is accounted for by known markers andgenes. Our results improve over previous studies in several ways.
First, we have more than 4 times as many SNPs as the largest
previous study (8.7 million vs. 2 million [Ridge et al., 2013b]).
Second, we have been able to incorporate evaluation of additional
recently discovered AD risk loci. Third, we have evaluated not just
known markers but gene regions associated with known markers
to test the hypothesis that additional, possibly rare markers in
regions of GWAS identiﬁed risk variants also impact risk for dis-
ease (Singleton and Hardy, 2011).
We report much higher genetic variance explained than previous
reports. This is likely because of the signiﬁcant increase in markers
used in our analysis, including many more rare variants than previ-
ouswork. Our estimate of the variance explained by APOEhaplotypes
is not signiﬁcantly different from our previous report (p ¼ 0.17;
13.42% and 5.92%, respectively) (Ridge et al., 2013b). However,
inclusion of the recently reported markers from the IGAP GWAS
(Lambert et al., 2013) and rare variants discovered using other
approaches have, as expected, accounted for a signiﬁcant increase in
variance explained by known markers (p ¼ 0.01; 16.3% compared to
7.78%) (Ridge et al., 2013b).
By evaluating all SNPs in the regions surrounding known AD
variants, we have evaluated the hypothesis of the existence of
pleomorphic risk loci proposed by Singleton and Hardy in 2011
(Singleton and Hardy, 2011). Such loci harbor both common and
rare variants that alter risk for common disease. Our results clearly
demonstrate that variation in the regions surrounding known AD
variants but not including known risk variants, accounts for 29% of
all genetic variance in AD, and 41% of remaining unexplained
genetic variance. This suggests that variants in these known AD risk
regions, which are not detectable with the study designs that have
been applied to date, contribute signiﬁcantly to variance in AD risk.
5. Conclusions
In summary, the results in Table 3 provide a clear assessment of
our progress in understanding genetic variance in AD. Most (69%) of
the genetic variance remains unexplained by known AD-risk vari-
ants. Much of the remaining variance is accounted for by genetic
P.G. Ridge et al. / Neurobiology of Aging 41 (2016) 200.e13e200.e20200.e16variation near already identiﬁed AD-risk variants, and other
important genetic regions remain to be discovered. As we have
discussed previously (Ridge et al., 2013b), these are likely to be rare
variants of varying effects and may also include gene  gene in-
teractions. Novel approaches to leveraging whole genome and
exome sequences in families (Cruchaga et al., 2014; Guerreiro et al.,
2012; Kauwe et al., 2013), or careful identiﬁcation of candidate
genes from other diseases (Guerreiro et al., 2012) or biological work
(Lu et al., 2014), will also facilitate identiﬁcation of additional var-
iants. Such work is vital to the development of therapeutics and
each gene represents a potential target for development.
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